Core Viewpoint - Haicheng Pharmaceutical has received approval from the National Medical Products Administration for the registration of Aximol capsules, which are indicated for patients with high triglyceride levels who do not respond adequately to other treatments [1] Group 1: Product Approval - The product Aximol is approved for use as a replacement or adjunct therapy to lower triglyceride levels in patients [1] - It is specifically indicated for Fredrickson Type IV hyperlipoproteinemia and Fredrickson Type IIb hyperlipoproteinemia [1] - The medication is to be used after dietary changes and other non-drug treatments, such as exercise and weight loss, have been attempted [1]

Group 1 - The core point of the article is that Haichen Pharmaceutical has received approval from the National Medical Products Administration for its product "Aximol" capsules [1] - Haichen Pharmaceutical's revenue composition for the year 2024 is entirely from the pharmaceutical manufacturing industry, accounting for 100.0% [2] - As of the latest report, Haichen Pharmaceutical has a market capitalization of 6.4 billion yuan [3] Group 2 - The article highlights that Chinese innovative drugs have generated $80 billion in overseas licensing this year, indicating a robust market for biopharmaceuticals [3] - There is a contrast noted between the hot secondary market for biopharmaceuticals and the cooling fundraising environment in the primary market [3]